Syntis Bio website screenshot

Syntis Bio

Syntis Bio is a clinical-stage biopharmaceutical company in Boston, Massachusetts developing oral therapies that use the small intestine as a delivery site. Its SYNT platform (Synthetic Tissue-lining) applies a mussel-inspired polydopamine polymer coating transiently to specific tissues in the GI tract, sustaining therapeutic activity for up to 24 hours before being naturally cleared. The platform is being applied to nutrient exclusion for obesity, gut-restricted enzyme replacement for rare metabolic disorders such as homocystinuria and maple syrup urine disease, and oral bioavailability enhancement for peptides and biologics. Lead candidate SYNT-101 is a once-daily oral pill intended to mimic aspects of gastric bypass by transiently blocking nutrient absorption in the duodenum. The company was co-founded in 2022 by MIT's Robert Langer and Giovanni Traverso with CEO Rahul Dhanda. Syntis Bio is a therapeutics developer and publishes no public API, developer program, SDK, or machine-readable specification.

Syntis Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Drug Delivery.

Syntis Bio’s developer surface includes engineering blog and 10 more developer resources.

10.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-09-02 · rubric v0.18.0
0 APIs
CompanyBiotechnologyPharmaceuticalsLife SciencesDrug DeliveryClinical StageObesityRare DiseaseHealth

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-09-02 · rubric v0.18.0
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/syntis-bio: open an issue to ask a question, or submit a pull request to add artifacts. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

Access & Security 1

Authentication, authorization, and security posture

Commercial 2

Pricing, plans, and the legal terms of use

Company 7

The organization behind the API

Scroll for all 7

Source (apis.yml)

apis.yml Raw ↑
aid: syntis-bio
name: Syntis Bio
description: Syntis Bio is a clinical-stage biopharmaceutical company in Boston, Massachusetts developing oral therapies that
  use the small intestine as a delivery site. Its SYNT platform (Synthetic Tissue-lining) applies a mussel-inspired polydopamine
  polymer coating transiently to specific tissues in the GI tract, sustaining therapeutic activity for up to 24 hours before
  being naturally cleared. The platform is being applied to nutrient exclusion for obesity, gut-restricted enzyme replacement
  for rare metabolic disorders such as homocystinuria and maple syrup urine disease, and oral bioavailability enhancement
  for peptides and biologics. Lead candidate SYNT-101 is a once-daily oral pill intended to mimic aspects of gastric bypass
  by transiently blocking nutrient absorption in the duodenum. The company was co-founded in 2022 by MIT's Robert Langer and
  Giovanni Traverso with CEO Rahul Dhanda. Syntis Bio is a therapeutics developer and publishes no public API, developer program,
  SDK, or machine-readable specification.
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://syntis.bio/wp-content/uploads/2024/06/logo-header.svg
url: https://raw.githubusercontent.com/api-evangelist/syntis-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pass-no-api-surface
specificationVersion: '0.20'
created: '2026-08-29'
modified: '2026-08-29'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Delivery
- Clinical Stage
- Obesity
- Rare Disease
- Health
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://syntis.bio/
- type: About
  url: https://syntis.bio/about/
- type: Blog
  url: https://syntis.bio/news/
- type: BlogRSS
  url: https://syntis.bio/feed/
- type: PrivacyPolicy
  url: https://syntis.bio/privacy-policy/
- type: TermsOfService
  url: https://syntis.bio/terms-of-use/
- type: Careers
  url: https://syntis.bio/careers/
- type: LinkedIn
  url: https://www.linkedin.com/company/syntis-bio/
- type: Twitter
  url: https://x.com/syntisbio
- type: DomainSecurity
  url: security/syntis-bio-domain-security.yml
- type: LLMsTxt
  url: llms/syntis-bio-llms.txt
x-enrichment:
  date: '2026-08-29'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Syntis Bio is a clinical-stage biopharmaceutical company whose product is an oral drug-delivery polymer (SYNT /
    SYNT-101), not software; syntis.bio is a single WordPress marketing site with no api./developer./docs. subdomain resolving,
    no GitHub organization, and a 404 on every OpenAPI, GraphQL and /.well-known/ path probed.
  evidence:
  - url: https://syntis.bio/openapi.json
    status: 404
  - url: https://syntis.bio/.well-known/api-catalog
    status: 404
  - url: https://syntis.bio/.well-known/agent-card.json
    status: 404
  - url: https://syntis.bio/graphql
    status: 404
  - url: https://syntis.bio/
    status: 200
  checked: '2026-08-29'

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this
  • find_providersBrowse and filter every provider in the catalog.
  • get_provider_artifactsEvery artifact this provider publishes, grouped by type.
  • get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
  • get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
  • get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
  • get_provider_ratingPRO — composite, band, trend and facet scores.
  • apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
  • resolveTurn a domain, URL or GitHub org into the provider it belongs to.
  • find_cohortsEvery scored population of providers in the catalog.
All 92 tools →

Call it yourself

curl for this page
This provider
curl "https://apis.io/api/v1/providers/syntis-bio"
All providers
curl "https://apis.io/api/v1/providers?limit=25"
Every operation they expose
curl "https://apis.io/api/v1/providers/syntis-bio/operations?limit=25"
How their score was established
curl "https://apis.io/api/v1/providers/syntis-bio/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

A second provider on the same verified email joins the account you already have.